Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Global anti-diabetic revenue by top ten pharmaceutical companies 2017 and 2024

Top 10 pharmaceutical companies by global anti-diabetic revenue in 2017 and 2024 (in million U.S. dollars)

by Matej Mikulic, last edited Aug 12, 2019
Global anti-diabetic revenue by top ten pharmaceutical companies 2017 and 2024 The top pharmaceutical companies based on global anti-diabetic revenue include big-name pharmaceutical leaders such as Novo Nordisk and Eli Lilly. As of 2017, Novo Nordisk was the top global anti-diabetic revenue generator with over 13.7 billion U.S. dollars in revenue for that year. Novo Nordisk is projected to continue being the top anti-diabetic pharmaceutical company by 2024. They are projected to make about 21 billion U.S. dollars in anti-diabetic pharmaceuticals revenue in the year 2024.

Diabetes treatments and prevalence

Diabetes is a chronic illness caused by the pancreas not producing enough insulin or the body not effectively using insulin. The global prevalence of diabetes in 2017 was about 8.8 percent and that is expected to increase significantly by 2045. Though not all countries are affected equally. Many Pacific Island nations have a significantly higher prevalence of diabetes than the rest of the world. Likewise, not all countries have the same standards of care or costs for care. Norway, Switzerland and the U.S. have the some of the highest costs per person with diabetes as of 2017.

Top diabetes pharmaceuticals

There are many types of treatments for diabetes. As of 2017, Novo Nordisk’s NovoRapid insulin held the highest share among all anti-diabetic products on the market. NovoRapid is primarily used in the treatment of type I diabetes. Other types of insulin are also among the top anti-diabetic products. When based on revenue generated, the top anti-diabetic products included Eli Lilly’s Trulicity and Boehringer Ingelheim’s Jardiance, medications used primarily in the treatment of type 2 diabetes.
Show more

Top 10 pharmaceutical companies by global anti-diabetic revenue in 2017 and 2024 (in million U.S. dollars)

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format

All Information
in one Presentation


Everything On "Diabetes" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Eli Lilly"
  • Global positioning
The most important statistics
  • Revenue and income
  • Expenses
  • Miscellaneous
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.